Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. Issue 3 (1st April 2020)

• Record Type: Journal Article
• Authors: El Ouali, Sara; Click, Benjamin; Holubar, Stefan D.; Rieder, Florian
• Is Part Of: United European Gastroenterology journal. Volume 8:Issue 3(2020)
• Page Start: 263
• Page End: 270
• Publication Date: 2020-04-01
• Subjects: Stricture -- stenosis -- fibrosis -- endoscopic balloon dilation -- surgery -- inflammatory bowel disease -- Crohn's disease; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640620901960
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract : Stricturing Crohn's disease (CD) is a significant clinical problem. The presence of a stricture may be suggested by clinical symptoms. Cross‐sectional imaging using computed tomography or magnetic resonance enterography is essential in diagnosing strictures as it allows further characterization and evaluation for complications such as abscess, fistulizing disease or malignancy. Managing small bowel stricturing CD should be approached in a multidisciplinary fashion. Medical therapy can be considered in strictures which are not associated with complications, with most of the data supporting anti‐TNF strategies in this setting. If the disease is refractory to medical therapy, endoscopic therapy or surgery should be performed. Endoscopic balloon dilation (EBD) is an option for short, uncomplicated and straight strictures that are within reach of a colonoscope. Although EBD has good short‐term outcomes, repeat dilation is often required. Surgical options mainly include resection and strictureplasty. Strictures refractory to medical therapy, not amenable or refractory to EBD, or associated with complications or malignancy should be managed surgically. However, surgery may also be considered at an earlier stage depending on disease characteristics and patient preference. Postoperative recurrence is common, highlighting the importance of careful monitoring of the patient postoperatively and optimization of medical management accordingly. There is a pressing need to develop anti‐fibrotics for the treatment of stricturing CD. This requires the development of standardized diagnostic criteria, patient‐reported outcome measures and validation of endpoints in fibrostenotic CD. The STAR consortium is pioneering this effort in order to allow development and testing of anti‐fibrotics in future clinical trials.